Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and

Elodie Henriet1, Hildur Knutsdottir2, Eloise M Grasset1

  • 1Department of Cell Biology, Center for Cell Dynamics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.

Oncogene
|January 5, 2023
PubMed

Insights

Heterogeneity in basal triple-negative breast cancer (b-TNBC) fuels metastasis. KRAS and ERK signaling pathways regulate distinct invasive phenotypes, offering potential therapeutic targets for b-TNBC.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Basal triple-negative breast cancer (b-TNBC) exhibits significant inter-patient and intra-tumoral heterogeneity, hindering biomarker identification and treatment strategies.
  • Tumor cell invasion, a critical step in metastasis, can occur through collective or single-cell migration.

Purpose of the Study:

  • To characterize the invasive phenotypes of b-TNBC organoids and identify molecular regulators driving these behaviors.
  • To investigate therapeutic targets for inhibiting b-TNBC invasion and dissemination.

Main Methods:

  • Primary b-TNBC organoids from a genetically engineered mouse model were cultured in 3D collagen gels.
  • Organoids were isolated based on invasive morphology for RNA sequencing, followed by shRNA knock-down experiments.
  • A drug screen targeting signaling pathways upstream and downstream of KRAS was performed.

Main Results:

  • Organoids displayed distinct invasive phenotypes: non-invasive, collective, and disseminative.
  • KRAS was essential for both collective and disseminative invasion.
  • Inhibition of EGFR, MAPK/ERK, and PI3K/AKT signaling pathways reduced invasion, with ERK inhibition being particularly potent.

Conclusions:

  • Individual cancer cells within the same b-TNBC tumor can exhibit diverse metastatic molecular programs.
  • KRAS and ERK signaling are critical regulators of both collective and single-cell dissemination in b-TNBC, representing potential therapeutic targets.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K